James Investment Research’s Altimmune ALT Stock Holding History

James Investment Research’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-268	Closed	-$19K	–	761
2017 Q3	$19K	Buy	+268	New	+$19.9K	﹤0.01%	696

Other funds holding ALT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

James Investment Research's ALT Position: Q4 2017 in Review

James Investment Research sold out of Altimmune (ALT) in Q4 2017, closing a stake of 268 shares — an estimated $19K sold.

James Investment Research first reported a position in ALT in Q3 2017 and held it in 1 quarter. The position peaked at $19K in Q3 2017. 30 funds tracked by Wall St. Rank hold ALT as of Q4 2017.

James Investment Research reported no remaining Altimmune position as of Q4 2017 after selling out during the quarter.
James Investment Research sold 268 Altimmune shares in Q4 2017, an estimated $19K.
James Investment Research first reported a position in Altimmune in Q3 2017 and held it in 1 quarter.
James Investment Research's Altimmune position peaked at $19K in Q3 2017.
30 funds tracked by Wall St. Rank held Altimmune as of Q4 2017.

Based on James Investment Research's 13F filing for Q4 2017, filed 23 Jan 2018.